Document:

EXHIBIT 10.39

AGREEMENT TERMINATING 

MANUFACTURING AND SUPPLY AGREEMENT

THIS AGREEMENT TERMINATING MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”), is entered into as of January 4, 2008, between BioMimetic Therapeutics, Inc., a Delaware corporation (f/k/a BioMimetic Pharmaceuticals, Inc.) (“BMTI”), and Luitpold Pharmaceuticals, Inc., a New York corporation (“Luitpold”). BMTI and Luitpold are each a “party” and are together, the “parties” to this Agreement.

WHEREAS, pursuant to a Manufacturing and Supply Agreement dated as of December 9, 2003, as amended (the “Manufacturing Agreement”), Luitpold is obligated to purchase all of its requirements for GEM 21S® Growth-factor Enhanced Matrix from BMTI and BMTI is obligated to meet such requirements, all on the terms and subject to the conditions thereof; and

WHEREAS, BMTI and Luitpold have entered into that certain Asset Purchase Agreement dated as of December 14, 2007 (the “APA”), whereby BMTI has agreed to sell and Luitpold has agreed to purchase all of BMTI’s assets primarily related to its orofacial therapeutic business (other than the Excluded Assets (as defined in the APA)); and

WHEREAS, in connection with the purchase and sale set forth in the APA, the parties wish to terminate the Manufacturing Agreement other than as herein provided.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows:

1. Termination. Notwithstanding anything to the contrary set forth therein, the Manufacturing Agreement and the parties’ respective rights and obligations thereunder are hereby terminated and shall be of no force and effect except as othewise provided herein.

2. Survival. Sections 6, 7.1, 9 and 12.1 of the Manufacturing Agreement shall survive its termination. In addition, outstanding payment obligations and all provisions of the Manufacturing Agreement shall survive its termination insofar as they govern the rights and obligations of the parties with respect to any Licensed Product ordered thereunder by, but not yet delivered to, Luitpold on the date hereof. 

3. Miscellaneous. This Agreement is subject to and shall be construed and enforced in accordance with the laws of the State of Delaware without reference to its choice of law provisions. This Agreement may be executed and delivered (including by facsimile transmission or e-mail with scan attachment) in two or more counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. This Agreement constitutes the entire agreement between the parties as to the subject matter hereof, and all prior negotiations, representations, agreements and understandings are merged into, extinguished by and completely expressed by this Agreement.

 

 

-1-

 

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first above written.

 

	
                         
 	
                         
 	
                        BIOMIMETIC THERAPEUTICS, INC.
 
	
                          
 	
                         
 	
                        By: 
 	
                        
 /s/ Samuel E. Lynch
 
	
                         
 	
                         
 	
                         
 	
                        Name: Samuel E. Lynch D.M.D., D.M.Sc.
 
	
                         
 	
                         
 	
                         
 	
                        Title: President and CEO
 
	
                         
 	
                         
 	
                         
 
	
                         
 	
                         
 	
                        LUITPOLD PHARMACEUTICALS, INC.
 
	
                          
 	
                         
 	
                        By: 
 	
                        
 /s/ Mary Jane Helenek
 
	
                         
 	
                         
 	
                         
 	
                        Name: Mary Jane Helenek
 
	
                         
 	
                         
 	
                         
 	
                        Title: President and CEO
 

 

 

-2-EXHIBIT 10.40

AMENDMENT AND WAIVER AGREEMENT

with respect to

ASSET PURCHASE AGREEMENT

THIS AMENDMENT AND WAIVER AGREEMENT WITH RESPECT TO ASSET PURCHASE AGREEMENT (this “Amendment”) is entered into and effective as of January 4, 2008, between BioMimetic Therapeutics, Inc., a Delaware corporation (“Seller”), and Luitpold Pharmaceuticals, Inc., a New York corporation (“Buyer”).

Reference is made to that certain Asset Purchase Agreement dated as of December 14, 2007 (the “Purchase Agreement”) between Seller and Buyer. All references to the Purchase Agreement, the Exhibits and Schedules thereto, and the Ancillary Agreements (as defined in the Purchase Agreement), shall be deemed to be references to the Purchase Agreement as amended by this Amendment. Terms used but not defined in this Amendment shall have the meanings ascribed to them in the Purchase Agreement unless otherwise provided herein.

RECITAL

WHEREAS, Seller and Buyer desire to amend and/or provide waivers with respect to certain provisions of the Purchase Agreement set forth more particularly in this Amendment.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, Seller and Buyer hereby agree as follows:  

1. Amendment. In accordance with Section 11.2 of the Purchase Agreement, the Purchase Agreement is hereby amended as follows:  

A. Schedule 1.1(d)(ii) to the Purchase Agreement is hereby deleted in its entirety and replaced with the attached Schedule 1.1(d)(ii).

B. Section 3.2 of the Purchase Agreement is hereby deleted in its entirety and restated as follows:  

“Section 3.2  Authorization. Seller has the full corporate power and authority to enter into this Agreement and the Ancillary Agreements and to carry out the transactions contemplated herein and therein. The Board of Directors of Seller has taken all action required by applicable Law and Seller’s certificate of incorporation and bylaws and otherwise to duly and validly authorize and approve the execution, delivery and performance by Seller of this Agreement, the Ancillary Agreements and the consummation by Seller of the transactions contemplated herein and therein. Without limiting the foregoing, neither the execution, delivery or performance by Seller of this Agreement or the Ancillary Agreements, nor the consummation by Seller of the transactions contemplated herein and
therein, requires the approval of the stockholders of Seller under applicable Law, Seller’s certificate of incorporation or bylaws, or otherwise. This Agreement has been duly and validly executed and delivered by Seller and assuming the due 

 

 

-1-

 

authorization, execution and delivery by Buyer of this Agreement and the Ancillary Agreements and Seller’s execution of the Ancillary Agreements at Closing, constitute or will constitute the legal, valid and binding obligations of Seller, enforceable against it in accordance with their respective terms.”

2. Waivers. In accordance with Section 11.2 of the Purchase Agreement, Seller and Buyer hereby mutually agree to the following waivers:  

A. Seller’s obligation to deliver to Buyer at Closing a transfer letter for the Canadian Medical Device License for GEM 21S as set forth in Section 2.4(h) of the Purchase Agreement is hereby waived; and

B. Buyer’s obligation to deliver to Seller at Closing an acknowledgment of Canadian Medical Device License transfer for GEM 21S as set forth in Section 2.3(g) of the Purchase Agreement is hereby waived;

provided, however, that Seller shall deliver to Buyer a transfer letter for the Canadian Medical Device License for GEM 21S at such time that Buyer becomes ISO certified in Canada for the manufacture of medical devices.

C. Seller’s obligation to deliver to Buyer a preliminary schedule of items to be included within the GEM 21S Inventory, prepared in good faith and executed by Seller in accordance with Section 2.4(i) of the Purchase Agreement, was satisfied by Seller’s delivery of Schedule 7.13 to the Purchase Agreement on the effective date thereof, and any further obligation to deliver such preliminary schedule at Closing is hereby waived. Seller hereby represents and warrants that such preliminary schedule remains true and correct in all respects at the date hereof.

3. Other Provisions Unaffected. All of the terms and provisions of the Purchase Agreement (as amended or modified by this Amendment) shall remain in full force and effect, and are hereby ratified and confirmed in their entirety.

4. Counterparts. This Amendment may be executed and delivered (including by facsimile transmission or e-mail with scan attachment) in two or more counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

 

 

-2-

 

IN WITNESS WHEREOF, Seller and Buyer have executed this Amendment as of the date first above written.

 

	
                        BIOMIMETIC THERAPEUTICS, INC.
 	
                         
 	
                        LUITPOLD PHARMACEUTICALS, INC.
 
	
      By:
 	
                        
 /s/ Samuel Lynch
 	
       
 	
      By:
 	
      
 /s/ Mary Jane Helenek
 
	
                        Name:
 	
                        Samuel E. Lynch D.M.D., D.M.Sc.
 	
                         
 	
                        Name:
 	
                        Mary Jane Helenek
 
	
                        Title:
 	
                        President & CEO
 	
                         
 	
                        Title:
 	
                        President & CEO
 

 

 

-3-EXHIBIT 10.41

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (“Agreement”) made effective as of January 1, 2008 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Samuel E. Lynch (the “Executive”).

In consideration of the mutual covenants contained in this Agreement, the parties hereby agree as follows:

1. Employment. The Company agrees to employ the Executive and the Executive agrees to be employed by the Company as President and Chief Executive Officer and to be responsible for the typical management responsibilities expected of an officer holding such position and such other responsibilities customarily pertaining to such office as may be assigned to the Executive from time to time by the Board of Directors of the Company (the “Board”), all for the Period of Employment as provided in Section 2 below and upon the terms and conditions provided in the Agreement. During the Period of Employment, the Executive shall manage the Company for the improvement of shareholder value to the best of his ability and perform faithfully the duties that may be assigned to him from time to time in
accordance herewith by the Board. 

2. Term. The period of Executive’s employment under this Agreement will commence as of January 1, 2008, and shall continue through December 31, 2012, subject to extension or termination as provided in this Agreement (“Period of Employment”). On January 1, 2013 and each January 1 thereafter, the Period of Employment will be extended for an additional one-year period, unless either party gives notice of non-extension at least 90 days prior to any such anniversary.

3. Compensation. For all services rendered by the Executive in any capacity during the Period of Employment, the Executive shall be compensated as follows:

(a) Base Salary. The Company shall pay the Executive an annual base salary of $410,000 (the “Base Salary”). The Base Salary shall be payable according to the customary payroll practices of the Company but in no event less frequently than once every two weeks. The Base Salary shall be reviewed each fiscal period and shall be subject to increase according to the policies and practices adopted by the Company from time to time, and at the discretion of the Board. 

(b) Incentive Compensation Award. The Executive shall be eligible to receive an annual incentive cash bonus as may be granted by the Board or the Compensation Committee of the Board under any executive bonus or incentive plan in effect from time to time (the “Annual Incentive Award”). The amount of any Annual Incentive Award shall be determined by the Compensation Committee based upon the satisfactory performance of goals set mutually by the Board and the Executive on an annual basis. 

 

 

(c) Stock Options. As set forth below, the Company will grant to the Executive options (the “Option”) to acquire one percent (1%) of the Company’s Common Stock on a fully diluted basis as of the effective date of this Agreement (which shall include all outstanding Common Stock, warrants and options and shares reserved for issuance pursuant to the Company’s stock option plan). The Option grant shall vest upon the earlier of the Company’s receipt of FDA approval of an orthopedic PDGF product or December 31, 2012. 

Each such Option grant shall be made pursuant to an Incentive Stock Option Agreement (“ISO Agreement”) between the Company and the Executive to the extent the Executive is eligible for incentive options under applicable tax laws and, with respect to any excess, or in the event the Executive is not eligible for incentive stock options, a Non-Qualified Stock Option Agreement (“NQSO Agreement”) between the Company and the Executive.   In all events each such Option shall be subject to the terms and conditions of the respective ISO Agreement or NQSO Agreement, as applicable, as well as the Company’s 2001 Stock Option Plan, as the same may be amended from time to time or any new long term incentive plan adopted by the Company. 

(d) Additional Benefits. The Executive will be entitled to participate in all employee benefit plans or programs and receive all benefits and perquisites for which any salaried employees are eligible under any existing or future plan or program established by the Company or its affiliates and available to any employees of the Company, including participation in any stock option plan. The Executive will participate to the extent permissible under the terms and provisions of such plans or programs in accordance with program provisions. These shall include, but not be limited to group hospitalization, health, dental care, participation in Company retirement and pension plans, life or other insurance and disability insurance. Nothing in this Agreement will preclude the Company or Company
affiliates from amending or terminating any of the plans or programs applicable to salaried employees or senior executives as long as the total value of all benefits is not materially decreased. The Executive will be entitled to an annual paid vacation of four weeks per year. 

4. Business Expenses and Other Expenses. The Company will reimburse the Executive for all reasonable travel and other business-related expenses and obligations incurred by the Executive on behalf of the Company.

5. Disability. 

(a) In the event of the disability of the Executive during the Period of Employment, the Company will continue to pay the Executive according to the compensation provisions of this Agreement during the period of his disability, until such time as any long term disability insurance benefits accruing to the Executive are available. However, in the event the Executive is disabled for a continuous period of six months, or for a total of 90 or more nonconsecutive days in any 270-day period, the Company may terminate the employment of the Executive. In this case, normal compensation will cease, except for earned but unpaid Base Salary and his monthly Base Salary as in effect at the time of termination for a period of six (6) months. 

 

 

2

 

(b) During the period the Executive is receiving payments of either regular compensation or disability insurance described in this Agreement and to the extent reasonable considering the Executive’s disability, the Executive will furnish information and assistance to the Company and from time to time will make himself available to the Company to undertake assignments consistent with his prior position with the Company. If the Company fails to make a payment or provide a benefit required as part of the Agreement, the Executive’s obligation to furnish information and assistance will end.

(c) The term “disability” will have the same meaning as under any disability insurance provided pursuant to this Agreement or otherwise.

6. Death. In the event of the death of the Executive during the Period of Employment, the Company’s obligation to make payments under this Agreement shall cease as of the date of death, except for earned but unpaid Base Salary. The Executive’s designated beneficiary will be entitled to receive the proceeds of any life insurance or other death benefit programs that may be provided by the Company.

7. Effect of Termination of Employment. 

(a) If the Executive’s employment terminates due to a Without Cause Termination, as defined below, or by the Executive for Good Reason, as defined below, or if the Company elects not to renew Executive’s employment hereunder, the Company will provide the Executive the following severance benefits: (i) continuation of the Executive’s Base Salary (and an amount equal to 1/12th of the most recent annual bonus and incentive award) on the Company’s regular payroll dates for a period equal to eighteen (18) months following the termination date; (ii) reimbursement to the Executive for the costs of the Executive’s group medical insurance premiums for himself and his dependents for the 18-month period immediately following his termination (or COBRA if applicable). Earned but unpaid Base Salary through the date of termination will be paid in a lump sum at such
time. Furthermore, all outstanding stock options, restricted stock, restricted stock units, and any other unvested equity incentives shall become fully exercisable and vested as of the Date of Termination (and shall remain exercisable for their stated terms, with the exception of any incentive stock options, which shall remain exercisable for three months following the Date of Termination)

(b) If the Executive’s employment terminates due to Termination for Cause (as defined below), material breach of this Agreement by Executive, or expiration of the Period of Employment as a result of the Executive giving notice of non-extension under Section 2 above, earned but unpaid Base Salary will be paid to the Executive on the termination date. No other payments will be made or benefits provided by the Company.

(c) For this Agreement, the following terms have the following meanings:

(i) “Termination for Cause” means termination of the Executive’s employment by the Board at any time after the occurrence of one or more of the following events, in each case as determined in good faith by the Board with Executive being afforded the opportunity of presenting his case to the Board: (a)

 

 

3

 

the Executive’s (i) willful misconduct or gross negligence in performance of his duties hereunder, or (ii) repeated refusal or failure to comply with the legal directives of the Board so long as such directives are not inconsistent with the Executive’s position and duties, which is not remedied (if remediable) within twenty (20) working days after written notice from the Board, which written notice shall state that failure to remedy such conduct may result in Termination for Cause; or (b) the Executive’s conviction of a felony or crime involving moral turpitude causing material harm to the standing and reputation of the Company.

(ii) “Without Cause Termination” means termination of the Executive’s employment (x) other than due to death, disability, or Termination for Cause, or  (y) as a result of the resignation by Executive for “Good Reason,” as defined below.(d) The Executive shall be entitled to receive benefits upon termination of his employment by the Company only as set forth in this Section 7 (and to the extent applicable, as set forth in Section 10). The Executive’s entitlement to such termination benefits shall be conditioned upon the Executive’s and Company’s execution and delivery of a mutual general release of claims and the resignation of Executive from all of the Executive’s positions with the Company and its affiliates, other than Executive’s position as a member of the Board. 

8. Other Duties of the Executive During and After the Period of Employment. 

(a) The Executive will, with reasonable notice during or after the Period of Employment, furnish information as may be in his possession and cooperate with the Company as may reasonably be requested in connection with any claims or legal actions in which the Company is or may become a party.

(b) The Executive recognizes and acknowledges that all non-public information pertaining to the affairs, business, clients, customers or other relationships of the Company, as hereinafter defined, is confidential and is a unique and valuable asset of the Company. Access to and knowledge of this information are essential to the performance of the Executive’s duties under this Agreement. The Executive will not during the Period of Employment and for 12 months thereafter except to the extent reasonably necessary in performance of the duties under this Agreement, give to any person, firm, association, corporation or governmental agency any non-public information concerning the affairs, business, clients, customers or other relationships of the Company, except as required by law. The Executive will not make use of this type of information for his own purposes or
for the benefit of any person or organization other than the Company. All records, memoranda, etc., relating to the business of the Company, whether made by the Executive or otherwise coming into his possession, are confidential and will remain the property of the Company. Confidential information shall not include information that (i) becomes generally available to the public other than as a result of disclosure by the Executive, (ii) was available to the Executive on a non-confidential basis prior to disclosure to the Executive in connection with his duties to the Company, provided that the source of such information is not known to the Executive to be bound by a confidentiality agreement or other contractual obligation of confidentiality to the Company or (iii) becomes available to the Executive on a non-confidential basis 

 

 

4

 

from a source other than the Company (or any agent, employee or affiliate of Company) provided such source is not known to the Executive to be bound by a confidentiality agreement or other contractual obligation of confidentiality to the Company. 

(c) During the period of his employment and for a period of 12 months thereafter, the Executive will not engage, directly or indirectly, in any business activity or enterprise which is a “Competitive Activity.”  For purposes hereof, “Competitive Activity” means any business or endeavor in which the Company is engaged at the Date of Termination (or, if the Date of Termination occurs after a Change in Control, immediately prior to the Change in Control, including if he becomes involved as an owner, employee, employer, consultant, principal, officer, director, independent contractor, agent, partner, advisor or in any other capacity, with or without compensation, calling for the rendition of personal services with any individual, partnership, corporation or other organization that is engaged in any part of the Competitive Activity; provided,
however, that the Executive will not be prohibited from owning less than one percent (1%) of any publicly traded corporation that is in competition with the Company. The Executive acknowledges that the covenants contained herein are reasonable as to geographic and temporal scope.

(d) The Executive acknowledges that his breach or threatened or attempted breach of any provision of this Section 8 would cause irreparable harm to the Company not compensable in monetary damages and that the Company shall be entitled, in addition to all other applicable remedies, to a temporary and permanent injunction and a decree for specific performance of the terms of this Section 8 without being required to prove damages or furnish any bond or other security.

(e) The Executive shall not be bound by the provisions of this Section 8 in the event of the default by the Company in its obligations under this Agreement that are to be performed upon or after termination of this Agreement.

(f) For purposes of this Section 8, the “Company” shall include any person or entity that, directly or indirectly, controls or is controlled by the Company or is under common control with the Company.

9. Indemnification; Litigation. The Company will indemnify the Executive to the fullest extent permitted by the laws of the state of incorporation in effect at that time, or certificate of incorporation and by-laws of the Company whichever affords the greater protection to the Executive. The Executive will be entitled to reimbursement of any reasonable fees or expenses incurred in connection with any action, suit or proceeding to which he may be made a party by reason of being a director or executive officer of the Company. The foregoing shall survive termination of the Executive’s employment or any future amendment or modification of the Company’s articles of incorporation or bylaws.

10. Effect of Change in Control. 

(a) In the event there is a Change in Control (as defined below) and within the twelve (12) month period following such event Executive is terminated in a Without

 

 

5

 

Cause Termination, the Company elects not to renew this Employment Agreement, or Executive elects to resign upon written notice to the Company following an event that constitutes Good Reason (as defined below), the Company shall pay to the Executive in a lump sum 150% of Executive’s Annual Base Salary and most recent Annual Incentive Award. Without limiting the foregoing, any Without Cause Termination or resignation for Good Reason that occurs within three (3) months prior to a Change in Control shall be deemed to be made in contemplation of such Change in Control. In addition, the Company shall pay Executive upon such termination or resignation, in exchange for Executive agreeing to not solicit any of the then current customers or employees of the Company for a period of twelve (12) months following his termination of employment, a lump sum payment of twelve (12) months of
his Base Salary plus an amount equal to 100% of the most recent annual bonus and incentive award.

(b) In addition, all unvested stock options and restricted stock held by Executive shall be deemed fully vested and immediately exercisable on the date of such Change in Control.

(c) A “Change in Control” shall be deemed to have occurred if (i) a tender offer shall be made and consummated for the ownership of more than fifty percent (50%) of the outstanding voting securities of the Company, (ii) the Company shall be merged or consolidated with another corporation or entity and as a result of such merger or consolidation less than fifty percent (50%) of the outstanding voting securities of the surviving or resulting corporation or entity shall be owned in the aggregate by the former shareholders of the Company, as the same shall have existed immediately prior to such merger or consolidation, (iii) the Company shall sell all or substantially all of its assets to another corporation or entity which is not a wholly- owned subsidiary, or (iv) a person, within the meaning of Section 3(a)(9) or of Section 13 (d)(3) (as in effect on the
date hereof) of the Securities and Exchange Act of 1934 (“Exchange Act”), shall acquire more than fifty percent (50%) of the outstanding voting securities of the Company (whether directly, indirectly, beneficially, or of record).

(d) For purposes hereof, ownership of voting securities shall take into account and shall include ownership as determined by applying the provisions of Rule 13d-3(d)(1)(i) (as in effect on the date hereof) pursuant to the Exchange Act.

(e) A resignation for “Good Reason” shall be deemed to have occurred if the Executive resigns his employment with the Company after the occurrence of any of the following events, to which the Executive has not expressly consented in writing: (i) a material reduction in the Executive’s Base Salary (other than one applicable to all executive officers); (ii) a material reduction in job duties, authority, responsibilities and requirements inconsistent with the Executive’s position with the Company and the Executive’s prior duties, authority, responsibilities, and requirements or a change in the Executive’s reporting relationship such that Executive is no longer reporting to the Board; (iii) a relocation of the Executive to a facility or location more than fifty (50) miles from the address of the Company’s headquarters office as of
the effective date of this Agreement, or (iv) material breach by the Company of any of the material covenants herein. Any of the foregoing conditions described in this Section 10(e) will constitute

 

 

6

 

“Good Reason” only if the Executive delivers a Notice of Termination identifying such condition within ninety (90) days after the initial existence of such condition and such condition must continue for a period of thirty (30) days after the delivery of such Notice of Termination.

11. Withholding Taxes.   The Company shall directly or indirectly withhold from any payments under this Agreement all federal, state, city or other taxes as required pursuant to any law or governmental regulation.

12. This Agreement is intended to comply with the requirements of Section 409A of the Internal Revenue Code and the regulations promulgated thereunder (“Section 409A”), and the Executive and the Company agree to interpret this Agreement in a manner consistent with Section 409A so as not to subject the Executive to the payment of interest or any additional tax under Section 409A. The parties further agree to modify or amend this Agreement as reasonably necessary to permit compliance with Section 409A, provided that such modification or amendment shall be accomplished in a manner that will not reduce the benefits payable to Executive.

13. Consolidation; Merger or Sale of Assets. Nothing in this Agreement shall preclude the Company from consolidating or merging into or with, or transferring all or substantially all of its assets to, another corporation that assumes this Agreement and all obligations and undertakings of the Company hereunder. Upon such a consolidation, merger or sale of assets, the term “the Company” as used will mean the other corporation and this Agreement shall continue in full force and effect. 

14. Modification. This Agreement may not be modified or amended except in writing signed by the parties. No term or condition of this Agreement will be deemed to have been waived, except in writing by the party charged with waiver. A waiver shall operate only as to the specific term or condition waived and will not constitute a waiver for the future or act on anything other than that which is specifically waived.

15. Effective Prior Agreements. This Agreement contains the entire understanding between the Company and the Executive with respect to the subject matter and supersedes any prior employment or severance agreements between the Company and its affiliates, and the Executive.

16. Governing Law. This Agreement has been executed and delivered in the State of Tennessee and its validity, interpretation, performance and enforcement shall be governed by the laws of that state.

17. Notices. All notices, requests, consents and other communications hereunder shall be in writing and shall be deemed to have been made when delivered or mailed first-class postage prepaid by registered mail, return receipt requested, or when delivered if by hand, overnight delivery service or confirmed facsimile transmission, to the following:

(a) If to the Company, at  BioMimetic Therapeutics, Inc., 389 A Nichol Mill Lane, Franklin, Tennessee 37067 with a copy to Mark Manner, Harwell Howard Hyne Gabbert & Manner, 315 Deaderick Street, Suite 1800, Nashville, Tennessee 37238, or at such other address as may have been furnished to the Executive by the Company in writing; or

 

 

7

 

(b) If to the Executive, at 6015 Saddleview Dr., Franklin, Tennessee 37067, or such other address as may have been furnished to the Company by the Executive in writing.

18. Binding Agreement. This Agreement shall be binding on the parties’ successors, heirs and assigns.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above written.

 

	
                         
 	
                         
 	
                         
 	
                        EXECUTIVE
 
	
                          
 	
                         
 	
                         
 	
                        
 /s/ Samuel Lynch
 
	
                         
 	
                         
 	
                         
 	
                        Dr. Samuel E. Lynch
 
	
                          
 	
                         
 	
                         
 	
                        
        2/27/08
 
	
                         
 	
                         
 	
                         
 	
                        Date
 
	
                         
 	
                         
 	
                         
 	
                         
 
	
                         
 	
                         
 	
                         
 	
                        BIOMIMETIC PHARMACEUTICALS, INC.
 
	
                          
 	
                         
 	
                         
 	
                        
 /s/ Chris Ehrlich
 
	
                         
 	
                         
 	
                         
 	
                        Chris Ehrlich, Chair of Compensation Committee
 of Board of Directors
 
	
                          
 	
                         
 	
                         
 	
                        
        February 26, 2008
 
	
                         
 	
                         
 	
                         
 	
                        Date
 

 

 

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]